Featured Oncology News
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Novartis’s $475,000 Price Tag on Cancer Drug Meets Resistance
New Study Determines Cancer Care Delivered In Hospital Outpatient Setting Much More Expensive Than In Independent, Community Oncology Practices
Viewpoint: FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Nashville, TN
[via telephone or webcast]
[via telephone or webcast]
Richmond, VA
[via telephone or webcast]
Barcelona, Spain
Singapore
Geneva, Switzerland
Atlanta, GA
[via telephone or webcast]
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
Washington, DC
San Francisco, CA
Indianapolis, IN
Washington, D.C.
National Harbor, MD
Chicago, IL
Amsterdam, The Netherlands
Phoenix, AZ
Phoenix, AZ
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Lilly Reports Topline Results from Phase 3 JUNIPER T...
October 10th 2017 by H. Jack West, MD
This is an unfortunate result, in a hard setting to treat. About 20% of patients with advanced NSCL...
Read More
TAGRISSO® (osimertinib) Granted Breakthrough Therap...
October 09th 2017 by H. Jack West, MD
The data from FLAURA definitely support a first line approval, and the NCCN has just revised their ...
Read More
New Study Determines Cancer Care Delivered In Hospit...
October 08th 2017 by patrick stagg
It was one of the reasons I was happy to retire from the hospital owned practice. Most physicians p...
Read More
Novartis Wants Japan To Link Drug Price To Patient O...
October 05th 2017 by Thomas Marsland, MD
This is an interesting concept. Although this sounds good it may not in the long run hold down drug...
Read More
Obinutuzumab vs Rituximab in FL: 'Too Close to Callâ...
October 05th 2017 by Dean Gesme, MD
An excellent editorial this past week in JCO authored by Jim Armitage and Dan Longo on this importa...
Read More
Proposed Changes to 340B Program Would Hurt Nonprofi...
October 04th 2017 by Thomas Marsland, MD
So clearly less is less..... but less for some maybe more for others. The hospitals have used ...
Read More
OBR Green